NAD+ 1G & RETATRUTIDE : A BRITISH UPDATE

The emerging interest in NAD+ supplementation, particularly at a substantial dosage of one gram, continues to rise within the UK healthcare community. Simultaneously , attention is firmly fixed on Retatrutide, a groundbreaking GLP-1 receptor agonist being viewed by many as a potential advancement